Similarly, other immune disorders and cancers may be treated with monoclonal antibodies targeting cancer-specific antigens or immunosuppressive molecules present on immune cells such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1). Here, CTLA4 is linked to immune system disorder.